Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

61. The safety, feasibility and effect of exercise-based interventions in prostate cancer patients with bone metastases receiving androgen deprivation therapy or chemotherapy: a systematic review

The safety, feasibility and effect of exercise-based interventions in prostate cancer patients with bone metastases receiving androgen deprivation therapy or chemotherapy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

62. Sun light exposure and the risk of prostate cancer: a systematic review

Sun light exposure and the risk of prostate cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

63. Adjuvant radiotherapy or salvage therapy? A prospective aggregate data meta-analysis of radiotherapy timing for treatment of intermediate or high risk localised prostate cancer

Adjuvant radiotherapy or salvage therapy? A prospective aggregate data meta-analysis of radiotherapy timing for treatment of intermediate or high risk localised prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

64. A systematic review and meta-analysis comparing multiparametric MRI-guided targeted biopsies and systematic biopsies in biopsy-na‹ve men suspected of having prostate cancer

A systematic review and meta-analysis comparing multiparametric MRI-guided targeted biopsies and systematic biopsies in biopsy-na‹ve men suspected of having prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

65. Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature based meta-analysis of randomized trials

Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature based meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

66. Systematic review and meta-analysis of the prognostic value of aberrations in the androgen receptor (AR) gene detected in cell-free DNA derived from castration-resistant prostate cancer patients

Systematic review and meta-analysis of the prognostic value of aberrations in the androgen receptor (AR) gene detected in cell-free DNA derived from castration-resistant prostate cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

67. The efficacy and quality of life of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis

The efficacy and quality of life of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

68. Effectiveness of proton therapy in comparison with standard and other types of radiation therapy in prostate cancer: umbrella review

Effectiveness of proton therapy in comparison with standard and other types of radiation therapy in prostate cancer: umbrella review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

69. Effectiveness of proton therapy in comparison with other types of radiation therapy in prostate cancer: a rapid review

Effectiveness of proton therapy in comparison with other types of radiation therapy in prostate cancer: a rapid review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

70. Computer-aided detection for prostate cancer diagnosis based on magnetic resonance imaging: a systematic review and meta-analysis

Computer-aided detection for prostate cancer diagnosis based on magnetic resonance imaging: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

71. Utilization of raman spectroscopy for diagnosis of prostate cancer: a systematic review and meta-analysis

Utilization of raman spectroscopy for diagnosis of prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

72. Traditional chinese medicine on treating pain caused by prostate cancer: a systematic review and meta-analysis

Traditional chinese medicine on treating pain caused by prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

73. The effect of peri-operative androgen deprivation therapy on cancer control in non-metastatic prostate cancer patients undergoing radical prostatectomy: a systematic review and meta-analysis

The effect of peri-operative androgen deprivation therapy on cancer control in non-metastatic prostate cancer patients undergoing radical prostatectomy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

74. Comparative evaluation of PSMA-targeted radiotracers versus f-18 fluclicolvine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis

Comparative evaluation of PSMA-targeted radiotracers versus f-18 fluclicolvine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

75. Efficacy and safety for use of bone modifying agents beyond 2 years of treatment in breast cancer and castration-resistant prostate cancer with bone metastases

Efficacy and safety for use of bone modifying agents beyond 2 years of treatment in breast cancer and castration-resistant prostate cancer with bone metastases Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

76. Impact of radiotherapy on survival in patients diagnosed with metastatic prostate cancer?a systematic review and meta-analysis

Impact of radiotherapy on survival in patients diagnosed with metastatic prostate cancer?a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

77. A systematic review of salvage focal therapies for localised non-metastatic radio-recurrent prostate cancer

A systematic review of salvage focal therapies for localised non-metastatic radio-recurrent prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

78. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer [Cochrane protocol]

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

79. Association between HSD3B1 variant and Castration-Resistant prostate cancer outcome: meta-analysis

Association between HSD3B1 variant and Castration-Resistant prostate cancer outcome: meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

80. Comparison of diagnostic efficiencies of different types of 18F-labeled tracers in various stages of prostate cancer

Comparison of diagnostic efficiencies of different types of 18F-labeled tracers in various stages of prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO